Introduction {#s0001}
============

The biochemistry of the canonical extracellular-signal-regulated kinases (ERK1/2) pathway is well studied: growth factor receptors activate Ras GTPases that recruit Raf kinase to phosphorylate MEK (mitogen-activated protein kinase kinase) which in turn phosphorylates ERK.[@cit0001] However, it is unclear how the signal specificity is achieved within the wide biological responses controlled by the ERK pathway. Scaffolding proteins facilitate interactions and functions of core signaling partners of the ERK pathway and play indispensable roles in controlling the specific ERK1/2 activities. Examples of proteins that assemble the components of the pathway into scaffolding complexes include proteins like kinase suppressor of Ras (KSR), MEK partner 1 (MP1)-p14 (LAMTOR2/3) complex, IQGAP and Shoc2.[@cit0002]

The first reference of Shoc2 in the literature is dated to the late 1990s, when Sur-8/Soc2, *suppressor of clear*, was isolated in *C. elegans* genetic screens[@cit0003] that identified several positive regulators of the universal ERK1/2 signaling pathway (e.g. *sem-5, soc-1*, and *ksr-1*).[@cit0006] Sur-8 had been predicted to function downstream of Ras and upstream of Raf and to possess no apparent catalytic activity.[@cit0003] Subsequent studies suggested that Sur-8/Shoc2 was capable of enhancing ERK1/2 activity by forming a ternary complex with Ras and Raf-1 kinase in response to stimuli from growth factors[@cit0008] and showed that Shoc2 can interact with several Ras isoforms.[@cit0004] The critical role of Sur-8/Shoc2 in modulating ERK1/2 activity became fully appreciated when Rodriguez-Viciana and co-workers found that silencing of Shoc2 abrogates ERK1/2 activity in various cell types even in the presence of oncogenic Ras and Raf mutations.[@cit0009] Embryonic mice lethality due to severe heart defects induced by the ablation of Shoc2 and the identification of the Shoc2 mutation in Noonan-like RASopathy patients further emphasized the critical role of Shoc2 in embryonic development.[@cit0010] Clearly, the Shoc2 scaffold plays an essential role in modulating ERK1/2, but our understanding of the mechanism by which Shoc2 controls this pathway is limited. In the present article, we discuss the recent advances in our understanding of Shoc2 function and the mechanisms by which it modulates ERK1/2 signaling.

Domain organization and sequence conservation of Shoc2 {#s0001-0001}
======================================================

Shoc2 is a 65 kDa protein expressed from humans to parasitic microorganisms with the 51% amino acids sequence similarity between *P. falciparum* and its human homolog. This striking conservation of Shoc2 implies that Shoc2 function is evolutionarily conserved as well.[@cit0012] All known Shoc2 orthologues are comprised of two major domains: the short, unstructured N-terminal domain followed by the long stretch of leucine-rich repeats (LRRs).[@cit0003] The well preserved N-terminal domain spans 85 amino acids in endothermic vertebrates and encompasses anywhere from 56 to 145 amino acids in other taxa.[@cit0012] Similar to other proteins that contain tandem arrays of multiple LRRs, Shoc2 is likely to form a horseshoe-shaped solenoid structure, which generates a platform holding several binding partners (i.e. PP1c, SCRIB, Erbin, HUWE1, PSMC5) ([Fig. 1](#f0001){ref-type="fig"}). The involvement of each known interacting partner in the regulation of Shoc2 function, assembly of the scaffolding complex, and/or subsequent control over the ERK1/2 signaling is discussed in following section. It is important to note that the last LRR contains a unique stretch of ∼20 amino acids that are responsible for the targeting of Shoc2 to late endosomes.[@cit0013] Figure 1.Schematic model depicting how ERK1/2 activity is transduced through the Shoc2 scaffold. Shoc2 routes Ras-Raf signals of the ERK1/2 pathway. (A) In the complex with Shoc2, PP1c dephosphorylates inhibitory Serine 259 of Raf-1 to facilitate signal transmission. (B) SCRIB competes with Shoc2 for PP1 binding thereby reducing ERK1/2 signaling. (C) Erbin disrupts the formation of Shoc2/Ras/Raf1 complexes to inhibit Shoc2-ERK1/2 signals. (D) Activation of the ERK1/2 pathway leads to an allosteric reversible ubiquitination of Shoc2 and, subsequently of Raf-1, by the E3 ligase HUWE1. HUWE1-mediated ubiquitination of Raf-1 fine-tunes its activity. In addition, ubiquitination triggers accumulation of Shoc2 complexes on the late endosomes/multi-vesicular bodies (LE/MVBs). On endosomes, Shoc2 complexes undergo remodeling by AAA+ ATPase PSMC5. The mechanoenzyme activity of this ATPases is utilized to reduce ubiquitination of Shoc2 and Raf-1 and, possibly, to reactivate the complex.

Shoc2 as a scaffolding protein - threshold control of ERK1/2 signaling {#s0001-0002}
======================================================================

Initially, scaffolding properties have been inferred for Shoc2 due to the apparent absence of an enzymatic activity and its ability to tether Ras and Raf-1 in close proximity. This notion of Shoc2 being a molecular platform that recruits enzymes to fine-tune signals transmitted through the scaffolding complex has since been supported by the several following studies. One such enzyme that interacts with Shoc2 is the catalytic subunit of the protein phosphatase 1 (PP1c) ([Fig. 1A](#f0001){ref-type="fig"}).[@cit0009] PP1c, known for its ability to cooperate with various regulatory proteins,[@cit0015] forms a holoenzyme with Shoc2. Owing to the high specificity of the Shoc2 interaction with M-Ras, the Shoc2-PP1c holoenzyme is targeted to stimulate Raf-1 kinase activity by dephosphorylating the S259 inhibitory site of Raf-1. The M-Ras/Shoc2/PP1c complex then activates Raf-1 recruited by other Ras proteins or Ras family GTPases.[@cit0009] It should be noted that the exclusivity of M-Ras binding to Shoc2 was challenged by others, and a consensus in regard to whether distinct Ras isoforms (H-Ras, K-Ras and N-Ras) form a direct complex with Shoc2 has yet to be reached. An unexpected feature of the M-Ras/Shoc2/PP1c complex was later revealed by Young et al. (2013), who showed that the M-Ras and Shoc2 dimer competes for PP1c binding with Scribbled Homolog (SCRIB) ([Fig. 1B](#f0001){ref-type="fig"}).[@cit0016] SCRIB, a member of the LAP (LRR and PDZ) proteins family, is a known regulator of the ERK1/2 pathway.[@cit0017] Young et al. showed that SCRIB antagonizes Shoc2-mediated Raf-1 dephosphorylation through a mechanism involving competition for PP1 molecules within the same scaffolding complex. Competition of Shoc2 and SCRIB for PP1c binding allows for the sophisticated mechanisms controlling the frequency and amplitude of Shoc2-transduced ERK1/2 activity thereby affecting establishment of cell polarity and tumorigenic growth.[@cit0016]

Erbin (also known as ERBB2IP) is another member of the LAP protein family and a Shoc2 interacting partner.[@cit0018] Analogous to SCRIB, Erbin is a suppressor of the growth factor-induced ERK1/2 activity. Erbin dampens ERK1/2 activity by sequestering Shoc2 and disrupting the Ras and Raf-1 interaction in keratinocytes and cardiomyocytes ([Fig. 1C](#f0001){ref-type="fig"}).[@cit0019] Both SCRIB and Erbin appear to provide an essential mechanism to control signaling strength of Shoc2-ERK1/2 activation.

ERK1/2 signals transduced by Shoc2 are fine-tuned through Shoc2 partnering with the proteins of the ubiquitin machinery: the HECT-domain E3 ubiquitin ligase HUWE1 and the AAA+ ATPase PSMC5.[@cit0013] HUWE1 and PSMC5 provide mechanism for the negative feedback that modifies the amplitude of Shoc2-mediated ERK1/2 signaling through allosteric post-translation modifications ([Fig. 1D](#f0001){ref-type="fig"}). Shoc2 ubiquitination is the first post-translational modification reported for Shoc2. The diversity of ubiquitin chains ligated to Shoc2 (K63, K48, K6, K11)[@cit0022] (unpublished data) indicates that this ubiquitination plays an active role in controlling Shoc2 function. Triggered by the activation of the ERK1/2 pathway, ubiquitination of Shoc2 by HUWE1 is a prerequisite for the subsequent ubiquitination of the Raf-1 kinase by the same E3 ligase.[@cit0022] The role of HUWE1 in controlling functions and levels of numerous essential proteins and cellular processes is reviewed in detail in Bernassola et al. 2008.[@cit0023] In the context of the Shoc2--Raf-1 scaffolding module, HUWE1 regulates the amplitude of ERK1/2 signal as well as the stability of both partners. Given that elevated levels of HUWE1 or somatic mutations have been found in several human pathologies,[@cit0024] it would be reasonable to expect that functions of Shoc2 and Raf-1, the dynamics of the ERK1/2 signaling pathway and the signaling network response are altered and contribute to these conditions.

An additional protein of the ubiquitin machinery involved in regulating Shoc2-mediated ERK1/2 signaling is the AAA+ ATPase (ATPase associated with diverse cellular activities) PSMC5. PSMC5 (rpt6 or Sug1), widely known for its essential role in the 19S proteasome,[@cit0028] also functions as an unfoldase/remodeler of APIS (AAA Proteins Independent of 20S) complexes.[@cit0030] In the Shoc2 assembly, PSMC5 has a unique role that does not involve control over stability of Shoc2 or its known partners. Here, PSMC5 governs the mechanism that controls dynamics of the Shoc2 transmitted ERK1/2 signals through remodeling of the Shoc2 complexes, sequestration of HUWE1 from the complex and modulating ubiquitination of Shoc2. Experiments using ATPase activity deficient mutants of PSMC5 demonstrated that ATP-fueled mechano-activity of PSMC5 is required for the remodeling of the Shoc2 complex in a spatially defined manner. Namely, PSMC5 remodels Shoc2 complexes and modulates ubiquitination of Shoc2 and Raf-1 when targeted to endosomes. By incorporating AAA+ PSMC5 unfoldase, Shoc2 complex acquires an additional layer of control over the amplitude of the ERK1/2 signals transmitted through the module. While HUWE1-mediated ubiquitination of Shoc2 and Raf-1 allows for the dynamic range of Raf-1 activity to be fine-tuned, PSMC5 controls the ability of HUWE1 to modify the noncatalytic scaffold Shoc2 thereby actively modulating the assembly of molecules in the complex.[@cit0013]

The role of Shoc2 in various biological processes {#s0001-0003}
=================================================

Given that aberrations in the mechanisms that control timing and amplitude of ERK1/2 signals have critical implications for numerous cellular processes, several studies have explored the biological significance of Shoc2. As mentioned above, the loss of Sur-8/Shoc2 in *C. elegans* was not lethal.[@cit0003] While the total ablation of Shoc2 in mice led to an early embryonic lethality, its endothelial knock-out resulted in multiple cardiac defects (e.g., the reduced mesenchyme proliferation phase during the atrioventricular canal (AVC) development progressing to the formation of hypoplastic endocardial cushions) and late embryonic lethality.[@cit0010] Demonstrating an essential role of Shoc2 in embryogenesis, this study had a surprising conclusion: Shoc2 is able to regulate AVC development in an ERK-independent manner.[@cit0010] The role of Shoc2 in differentiation and proliferation of neuronal progenitor cells (NPCs) was examined using lentivirus-mediated Shoc2 knock-down.[@cit0032] In this model, Shoc2 acted as an anti-differentiation factor that stimulated ERK signals to NPCs proliferation and self-renewal.[@cit0032] The ability of Shoc2 to increase self-renewal was attributed to the cellular mechanisms controlling the protein stability of Shoc2. The authors of this study also suggested that Shoc2 might be a potential stem cell marker for NPCs.

Addressing the potential role of Shoc2 in tumorigenesis, several studies examined the ability of Shoc2 to increase ERK1/2 signals in various types of malignant cells (e.g. pancreatic, colon, breast and non-small cell lung carcinoma, melanoma, neuroblastoma, fibrosarcoma, and hepatoma cells).[@cit0009] Using siRNA silencing of Shoc2, Rodriguez-Viciana et al. demonstrated that Shoc2 was able to accelerate ERK1/2 activity even in cancer cells that carry tumorigenic K-Ras, N-Ras and B-Raf mutations.[@cit0009] While deciphering mechanisms responsible for the acquired resistance of melanomas to the B-Raf inhibitor vemurafenib (PLX4032), Kaplan et. al found that Shoc2 mediates reactivation of the ERK1/2 pathway in cells with constitutively active N-Ras.[@cit0035] Shoc2 facilitated melanoma-acquired vemurafenib resistance by altering signaling connections and re-routing oncogenic N-Ras signals to Raf-1.[@cit0035] Activity of ERK1/2 transduced by Shoc2 was shown to contribute to the malignant properties of different tumor cells via regulating contact inhibition, anchorage-independent proliferation and orientation of the microtubule-organizing center of these cells.[@cit0016] We showed that Shoc2 modulates ERK1/2 signals to cell motility and attachment, in part, through regulating expression of the protein of extracellular matrix - lectin galactoside-binding soluble 3-binding protein (LGALS3BP).[@cit0034] This secreted glycoprotein forms oligomers in the extracellular milieu and promotes cell adhesion to matrix proteins. High levels of LGALS3BP in serum and tumor tissue are associated with a shorter survival in patients with various malignancies.[@cit0037]

Germline mutations in genes encoding proteins of the ERK1/2 pathway trigger RASopathies -- developmental disorders characterized by distinct facial features, developmental delays, cardiac defects, growth delays, neurologic issues, gastrointestinal difficulties and predisposition to certain types of cancers.[@cit0039] In 2009 Cordeddu and coworkers reported that the c.4A\>G missense mutation in the SHOC2 gene leads to a distinctive RASopathy termed Noonan-like syndrome with loose anagen hair.[@cit0011] c.4A\>G, p.S2G substitution subsequently leads to a protein with the abnormally added myristate fatty acids that is aberrantly targeted to the plasma membrane. The first group of patients carrying c.4A\>G mutation were reported to have an unusual combination of features where reduced growth associated with growth hormone deficiency, cognitive deficits, distinctive hyperactive behavior, and a unique hair anomaly (*i.e.*, loose anagen hair). These findings were then expanded from distinctive craniofacial dysmorphisms and a wide spectrum of congenital heart defects to variable neurocognitive impairments, brain anomalies, epilepsy, severe hydrops fetalis and even Moyamoya syndrome, and also questioned the association of Shoc2 mutations with 'loose anagen hair' pointing to its speculative nature.[@cit0041] The biological complexity of Shoc2 S2G patients was explored using transcriptome analysis of peripheral blood mononuclear cells.[@cit0048] A large transcriptional signature characterized for the Shoc2 S2G mutation indicated a unique, Shoc2-specific route for the signaling it controls. Interestingly, the alterations in the expression of transcription factors (TFs) found in Shoc2 (S2G) patients had very little overlap with identities of TFs expression affected by the depletion of Shoc2, emphasizing the selective effect point mutation may have on ERK1/2 activity.[@cit0034]

A different Shoc2 substitution (c.519G\>A; p.M173I) was recently reported by Hannig et al. (2014) in patients with the mild Noonan-like RASopathy.[@cit0049] De-novo occurrence of this Shoc2 mutation and a typical clinical phenotype suggested the mutation to be pathogenic, while the analysis of the molecular mechanisms underlying the Noonan-like pathology pointed to an impaired ability of the Shoc2 M173I mutant to interact with PP1C. It is worth mentioning that a similar substitution of the methionine 173 (c. 517A\>G, p.M173V) was found in Noonan syndrome patient by the Kuechler et al.,[@cit0050] but no underlying molecular mechanisms were proposed. Recognizing a clinical variability in patients with the Shoc2-linked RASopathy, it is likely that individuals with no molecularly confirmed mutations carry different or already known Shoc2 substitutions.[@cit0051]

Conclusions and closing remarks {#s0001-0004}
===============================

Scaffolding proteins are reported to have critical roles in an increasing number of biological signaling processes.[@cit0052] Some of these scaffolds show surprising dynamics/diversity in the ways in which they bring multiple binding partners together to facilitate their interactions and functions that are beyond a simple tethering mechanism to increase the efficiency of interaction.[@cit0053]

Initial insights regarding the structural and functional studies of Shoc2 have started to expose the intricacy of the mechanisms controlling function of the scaffold and assembly of the complex. Advances made in the past few years have emphasized the central position of Shoc2 in the ERK1/2 pathway and cellular processes it controls. Nevertheless, several gaps remain to be filled in order to understand the intricacy of the Shoc2 machinery and biological activities controlled by the module. First, it would be important to identify all the proteins assisting in the process of the Shoc2 scaffold assembly and remodeling. Moreover, there is the question of the stimuli that activate assembly and control subcellular distribution of the Shoc2 scaffolding complex. The final effects of Shoc2 and Raf-1 ubiquitination are yet to be understood. Further research regarding the possible contribution of Shoc2 interactions to skin diseases, like psoriasis, or cardiac hypertrophy as well as more insights on Shoc2-ERK1/2 physiological substrates and cellular outcomes will determine whether Shoc2 is an attractive therapeutic target. Finally, additional studies of Shoc2 will provide fundamental insights into our understanding of the mechanisms by which other scaffolds may be controlled.
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